Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications
First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study.
Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026
Role of tankyrase scaffolding in the β-catenin destruction complex and WNT signaling.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 11, 2025
First Measurement: Proactive Immune Cell Sparing in Radiation Therapy.
Journal: medRxiv : the preprint server for health sciences
Published: January 20, 2025
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2025
Impact of CRISPR in cancer drug discovery.
Journal: Science (New York, N.Y.)
Published: October 24, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.
Journal: Cancer research communications
Published: August 31, 2024
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies.
Journal: Expert opinion on biological therapy
Published: July 29, 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Journal: Journal for immunotherapy of cancer
Published: February 28, 2024
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
Journal: Cancer research communications
Published: February 20, 2024
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Journal: Journal of neuro-oncology
Published: December 13, 2023
Last Updated: 09/26/2026